CJC-1295
Growth Hormone, IGF-1 & GHRH-Axis Research
SUPPORTED BY HUMAN RESEARCH
NOT ESTABLISHED
NOT APPROVED
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland to release the body's own growth hormone.
FDA describes CJC-1295 as a 29-amino-acid peptide. An important complication is that several chemically distinct substances are marketed under the CJC-1295 name, including forms with and without a Drug Affinity Complex (DAC). FDA has specifically cautioned that these different forms should not automatically be treated as interchangeable.
The best-characterized form in published human studies appears to be CJC-1295 with DAC. The DAC modification allows the peptide to bind to circulating albumin, greatly extending its activity compared with naturally occurring GHRH.
Important: CJC-1295 is not human growth hormone. It works upstream by stimulating the body's GH/IGF-1 axis.
Why Are Researchers Interested?
Natural GHRH has a short duration of action. Researchers developed CJC-1295 in an attempt to create a longer-lasting compound capable of stimulating endogenous GH secretion. Research interest has centered on:
Early human studies produced clear evidence that the DAC form can substantially and persistently influence GH and IGF-1 concentrations. What has not been established is whether these hormonal changes reliably translate into the many wellness, fitness, recovery, or anti-aging benefits commonly attributed to CJC-1295.
What The Research Suggests
CJC-1295 Can Significantly Increase GH and IGF-1
The best-known human study was published in the Journal of Clinical Endocrinology & Metabolism in 2006. Researchers conducted two randomized, double-blind, placebo-controlled dose-escalation studies in healthy adults.
After a single subcutaneous dose, researchers reported: mean GH concentrations increased approximately 2- to 10-fold; GH remained elevated for six days or longer; mean IGF-1 concentrations increased approximately 1.5- to 3-fold; IGF-1 remained elevated for approximately 9–11 days; and the estimated CJC-1295 half-life was approximately 5.8–8.1 days. With repeated administration, IGF-1 remained above baseline for as long as 28 days.
This is strong evidence that the studied CJC-1295 material can influence the human GH/IGF-1 endocrine axis. It is not, by itself, evidence that CJC-1295 produces clinically meaningful fat loss, muscle gain, anti-aging effects, or athletic improvement.
Growth Hormone Secretion Remains Pulsatile
An interesting question was whether prolonged stimulation from a long-acting GHRH analog would eliminate the body's normal pulsatile GH secretion. A second human study evaluated healthy men before and approximately one week after CJC-1295 administration.
Researchers found that pulsatile GH secretion persisted despite the prolonged stimulation, suggesting that CJC-1295 did not simply create a continuous nonphysiologic GH signal. This is one reason CJC-1295 attracted interest as a potential alternative strategy to directly administering recombinant growth hormone. Again, preservation of GH pulsatility is a physiological finding, not proof of a specific clinical benefit.
CJC-1295 With DAC Has a Prolonged Effect
The DAC modification is one of the defining characteristics of the original long-acting compound. FDA's scientific review explains that CJC-1295 DAC was designed to bioconjugate with endogenous serum albumin, which may protect the peptide against rapid degradation and contribute to its longer duration of activity.
Published human studies report an estimated half-life of approximately one week for the studied DAC compound. This makes it very different from native GHRH and from compounds marketed as “CJC-1295 without DAC.”
Increasing GH Does Not Automatically Establish Muscle Growth or Fat Loss
Growth hormone and IGF-1 influence numerous tissues and metabolic pathways. For that reason, CJC-1295 is frequently marketed for increasing lean muscle, decreasing body fat, improving exercise recovery, improving sleep, increasing energy, improving physical performance, and “anti-aging.”
The scientific problem is that the principal controlled human trials of CJC-1295 were designed primarily to evaluate pharmacokinetics, GH, IGF-1 and short-term safety in healthy volunteers. FDA's detailed review found no clinical effectiveness data establishing the evaluated CJC-1295 substances as treatments for growth hormone deficiency, the indication considered during its compounding review. There is even less controlled evidence demonstrating the broad wellness and body-composition claims frequently encountered online.
Evidence At A Glance
Raising Growth Hormone
Controlled studies demonstrated sustained increases in circulating GH following administration of the studied CJC-1295 DAC material.
Raising IGF-1
Human studies demonstrated sustained, dose-dependent increases in IGF-1.
Preserving GH Pulsatility
GH secretion remained pulsatile approximately one week after administration in healthy men.
Growth Hormone Deficiency Treatment
FDA found no effectiveness evidence demonstrating that the evaluated CJC-1295 substances effectively treat growth hormone deficiency.
Muscle Growth / Body Recomposition
The hormonal mechanism provides a research rationale, but meaningful body-composition outcomes have not been established in adequate controlled human trials.
Anti-Aging / Longevity
Increasing GH or IGF-1 should not be interpreted as evidence of longer life or reversal of biological aging.
Safety & Limitations
Human exposure to CJC-1295 has been limited, and most published clinical research involved relatively small numbers of healthy adults for short periods. FDA notes that this makes it difficult to determine the safety of chronic treatment or use in populations different from those studied.
Adverse Events in Human Studies
FDA's review identified adverse events including injection-site redness, irritation, pain or itching; headache; flushing and warmth; transient reductions in blood pressure; increased heart rate; nausea or abdominal discomfort; diarrhea; and dizziness. In the principal early study, injection-site reactions occurred frequently, and some adverse events became more common at higher doses.
FDA's current compounding safety resource specifically identifies increased heart rate and systemic vasodilatory reactions among serious safety concerns associated with CJC-1295 and emphasizes that available clinical data remain limited.
Elevated GH and IGF-1 Require Caution
Because CJC-1295 increases endogenous GH and IGF-1, FDA notes that safety issues associated with elevated activity of this pathway deserve consideration. FDA-approved recombinant GH products carry warnings involving issues such as glucose intolerance and diabetes, fluid retention, intracranial hypertension, certain endocrine disturbances, and neoplasm-related concerns.
FDA has not established that CJC-1295 necessarily carries exactly the same risks, but it also has not established that it does not.
Long-Term Safety Is Unknown
FDA found that most subjects in the available CJC-1295 studies received limited exposure and that the trials were too small and too short to adequately determine long-term safety. FDA specifically states that the long-term human safety profile is unknown.
That means absence of frequent serious events in early trials should not be interpreted as proof of long-term safety.
Peptide Quality and Immunogenicity
FDA has also raised concerns regarding compounded CJC-1295 involving peptide aggregation, peptide-related impurities, API characterization, manufacturing variability, and potential immunogenicity. FDA notes that injectable peptide products may pose particular immunogenicity concerns and that peptide stability and biological activity can be highly dependent on manufacturing quality.
FDA's current safety page states that compounded drugs containing CJC-1295 may pose immunogenicity risks and that the available clinical data are limited.
Animal Safety Findings Require Further Investigation
FDA's nonclinical review identified findings in animals that warrant caution. Repeated injections of CJC-1295 DAC in rats and dogs produced local findings including hemorrhage, inflammation and tissue necrosis at injection sites under the experimental conditions studied.
FDA also identified genotoxicity signals in certain experimental systems and noted that adequate long-term carcinogenicity studies were lacking. These findings do not establish that CJC-1295 causes cancer or these same effects in humans. They demonstrate why more long-term safety research is necessary.
Regulatory Status
No. CJC-1295 is not FDA-approved for any therapeutic indication. FDA states that none of the CJC-1295-related substances it evaluated are components of FDA-approved drugs. It is not FDA-approved for growth hormone deficiency, muscle growth, weight loss, fat loss, body recomposition, exercise recovery, sleep improvement, anti-aging, longevity, or general wellness.
What About Compounding?
This is particularly important for CJC-1295. FDA evaluated five related bulk drug substances: CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate. FDA's scientific evaluation concluded that the available evidence weighed against placing these substances on the 503A Bulks List.
At the December 4, 2024 Pharmacy Compounding Advisory Committee meeting, the committee voted against inclusion of every evaluated CJC-1295 form. FDA's current compounding information also continues to identify CJC-1295 as a substance that may present significant safety risks when used in compounded drugs.
Regulatory Status: Not FDA-Approved — CJC-1295 is not FDA-approved for any therapeutic indication. FDA evaluated CJC-1295-related bulk drug substances under Section 503A and identified significant unresolved issues involving clinical evidence, long-term safety, product identity, impurities, and immunogenicity. Future regulatory status cannot be predicted.
CJC-1295 With DAC vs. Without DAC
This distinction is important enough that it should be made explicit. FDA has emphasized that multiple CJC-1295 forms and derivatives exist and that identity and naming can be confusing.
CJC-1295 With DAC
The form most closely associated with the original published human CJC-1295 research. The Drug Affinity Complex enables the molecule to associate with serum albumin and substantially prolongs its activity. The human study reported an estimated half-life of approximately 5.8–8.1 days.
“CJC-1295 Without DAC”
Products marketed as CJC-1295 without DAC are commonly associated with a different GHRH analog often called Modified GRF (1-29). FDA's review found that the available human clinical studies appeared to involve CJC-1295 DAC, while FDA did not identify equivalent human clinical data for the other evaluated forms.
Why the Difference Matters: Human data showing a roughly one-week half-life, sustained GH elevation, and sustained IGF-1 elevation should not automatically be attributed to a product marketed as “CJC-1295 without DAC.” Different structures can have different pharmacokinetics, biological activity, safety profiles, and manufacturing considerations.
Research & Publications
FDA Scientific Review — CJC-1295-Related Bulk Drug Substances
U.S. Food and Drug Administration — December 2024
FDA's extensive review covering CJC-1295 identity, DAC and non-DAC forms, pharmacology, human studies, adverse events, toxicology, immunogenicity, effectiveness, and pharmacy-compounding considerations.
View FDA CJC-1295 Scientific ReviewFDA Pharmacy Compounding Advisory Committee — Final Minutes
U.S. Food and Drug Administration — December 2024
Official FDA meeting record documenting the committee's votes against inclusion of the five evaluated CJC-1295-related bulk drug substances on the 503A Bulks List.
View FDA Final Meeting MinutesProlonged GH and IGF-1 Stimulation by CJC-1295
Journal of Clinical Endocrinology & Metabolism — 2006
Randomized, placebo-controlled human research demonstrating prolonged, dose-dependent increases in GH and IGF-1 following subcutaneous administration of the studied CJC-1295 DAC material.
View on PubMedGH Pulsatility During CJC-1295 Administration
Journal of Clinical Endocrinology & Metabolism — 2006
A human study evaluating growth-hormone secretion patterns after CJC-1295 administration. Researchers found that pulsatile GH secretion persisted despite prolonged stimulation.
View on PubMedIdentification of CJC-1295 in an Unregulated Pharmaceutical Preparation
Drug Testing and Analysis — 2011
Researchers used analytical techniques to identify CJC-1295 in an unknown pharmaceutical preparation and discussed its availability outside formal clinical-development channels.
View on PubMedFDA — Potential Safety Risks With Compounded CJC-1295
U.S. Food and Drug Administration
FDA discusses immunogenicity, peptide-related impurities, API characterization, increased heart rate, systemic vasodilatory reactions, and limitations of available clinical evidence.
View FDA Compounding Safety ResourceFDA — Section 503A Bulk Drug Substance Requirements
U.S. Food and Drug Administration
Explains the federal framework governing bulk drug substances that state-licensed pharmacies and physicians may use when compounding under Section 503A.
View FDA 503A Compounding InformationCJC-1295 is an investigational growth hormone-releasing hormone analog with human evidence demonstrating that the studied DAC form can substantially increase growth hormone and IGF-1 levels.
That biological effect should not be confused with established clinical treatment benefits. Increasing GH and IGF-1 does not by itself prove that CJC-1295 produces meaningful muscle growth, fat loss, better sleep, faster recovery, improved athletic performance, anti-aging effects, or increased longevity.
The strongest published human research involved relatively small numbers of healthy adults and appears to have involved CJC-1295 with DAC. Evidence for products marketed as CJC-1295 without DAC is substantially less developed, and data from one form should not automatically be applied to another.
CJC-1295 is not FDA-approved for any therapeutic indication, and FDA has identified significant unresolved issues involving clinical evidence, long-term safety, product identity, impurities, and immunogenicity.
This page is provided for educational purposes only. CJC-1295 is not offered for sale, prescription, or distribution through this website.